Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Torametinib + fruquintinib + hydroxychloroquine in RAS/BRAF V600E-mutant refractory advanced colorectal cancer
ChiCTR2500102053Phase 2Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Apr 2025
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of trametinib, fruquintinib and hydroxychloroquine in colorectal cancer (CRC) (2 cohorts), sponsored by Peking Union Medical College Hospital. Primary endpoint: Objective response rate. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
trametinibfruquintinibhydroxychloroquine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2500102053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102053.